Biofrontera (BFRI) Q3 2026 earnings review
Biofrontera wins skin cancer approval, but legal costs drain cash
Biofrontera, a dermatology company selling light-activated skin treatments, cleared its two biggest regulatory hurdles while its cash cushion shrank. Third-quarter revenue rose 30% from a depressed year-ago period to $9 million as clinics stocked up on Ameluz gel before a July lamp import ban took effect. In September, Chief executive Hermann Luebbert won both FDA approval to treat skin cancer and a Customs ruling allowing its redesigned lamp into the country.
| Net product revenue | $9.1M +29.8% from a year ago |
|---|---|
| Gross margin | 74.4% +3.7 percentage points from a year ago |
| Cash and cash equivalents | $3.2M $4.7M last quarter |
| Skin cancer launch plan | Unchanged late Q4 2026 into Q1 2027 |
⚖️ Verdict: 🟢 Bullish
The story got better because both binary regulatory risks resolved in the company's favor within five days, reopening the blocked lamp base and unlocking the 2027 skin cancer launch. The bad news: legal bills and lamp replacement costs pushed operating losses back to $6 million and drained cash to $3 million, while preferred stock conversions increased the common share count by 26% in a single quarter by our math.
The question now is whether fourth-quarter holiday sales can generate enough cash to fund the skin cancer launch without raising more dilutive capital. Either high-margin fourth-quarter orders cover the $3 million nine-month cash burn and fund operations, or low liquidity forces another financing round as existing preferred holders keep converting into common shares. Full-year cash flow and the fourth-quarter share count will settle it.
🐂 Bull Case
FDA Approves Ameluz for Skin Cancer
Biofrontera sells Ameluz, a prescription gel paired with its RhodoLED red-light lamps for photodynamic therapy (PDT), a light-activated skin treatment. Until September, US dermatologists could only prescribe it on the face and scalp for actinic keratosis, a pre-cancerous skin lesion. Growth in 2027 depended on expanding the drug's approved uses.
On September 9, the Food and Drug Administration approved Ameluz for superficial basal cell carcinoma (sBCC), making it the first photodynamic therapy cleared in the US for cancerous skin tumors. One month later, on October 8, the dermatology company applied to expand its actinic keratosis label to the extremities, neck and trunk.
Chief executive Hermann Luebbert noted that "Each of these indications is served by the lamps and the sales force we already have in place". Because dermatologists already own the lamps, new skin cancer prescriptions require no extra hardware investment from doctors or new sales hires from the US company.
What to watch: first-quarter 2027 revenue and order volumes, which arrive after the full skin cancer rollout begins. A step-up in tubes ordered per clinic would show doctors are adopting the treatment for cancer patients.
Customs Ruling Restores Blocked Lamp Sales
On July 6, an International Trade Commission (ITC) import ban took effect against Biofrontera's larger RhodoLED XL lamp in a patent dispute, barring the company from selling Ameluz to roughly 30% of its installed lamp base. To restore access, engineers redesigned the device as the RhodoLED XL-C.
On September 14, US Customs and Border Protection ruled that the redesigned XL-C does not violate the exclusion order, and the company began placing the new lamps before September ended. Luebbert said the decision "allows us to again serve the customers who rely on our large-field lamp". Third-quarter sales rose 29.8% from a year ago to $9.1 million, helped by 23.3% growth in Ameluz unit volume.
The Customs win clears the main operational bottleneck, but third-quarter revenue does not yet prove normal demand returned. Sales benefited from an easy comparison against a weak year-ago quarter and from "accelerated order timing from certain customers in early July 2026 in anticipation of potential supply restrictions" before the ban took effect.
What to watch: fourth-quarter revenue against last year's record $17.1 million peak. Holding or beating that mark would confirm that clinics have swapped their old lamps and resumed regular seasonal ordering.
New Supply Terms Keep Product Margins High
In October 2025, Biofrontera bought the US rights to its products from its former German parent, Biofrontera AG. That deal replaced a transfer price of 25% to 35% of sales with direct manufacturing costs plus a 12% royalty on US revenue under $65 million.
In the third quarter, cost of revenues — the cost of buying the gel and lamps — fell to 25.6% of sales from 29.3% a year ago, lifting gross margin 3.7 percentage points to 74.4%. Excluding $0.3 million of inventory write-downs from the lamp dispute, gross margin was 77.9% by our math, keeping nine-month gross margin at 78.0% despite higher device replacement costs.
What to watch: fourth-quarter gross margin once initial XL-C lamp swaps finish. A rebound toward 80% during the holiday selling peak would confirm that the third-quarter dip came only from temporary device replacement charges.
🐻 Bear Case
Cash Drops to $3.2 Million as Losses Widen
"The quarter also carried the legal and remediation costs of the ITC Matter, and with the XL-C now cleared our attention is on execution," Luebbert said. Across the past year, executives have targeted reaching operating cash-flow breakeven for full-year 2026 while operating under a going-concern warning.
Instead of narrowing, operating losses widened back to $6.5 million in the third quarter from $0.5 million in the second quarter. Selling, general and administrative expenses — sales commissions, legal bills and overhead — climbed $2.1 million from a year ago to $12.5 million, or 137.7% of revenue.
- Cash and cash equivalents: $3.2 million at September 30, down from $4.7 million in June and $6.4 million at year-end
- Third-quarter operating cash burn: about $1.5 million by our math, nearly matching the $1.7 million used in the entire first half
- Legal and regulatory drivers: $0.9 million higher ITC legal fees and $0.7 million in new manufacturing and regulatory overhead
- Convertible debt due November 2027: $4.7 million, leaving $1.5 million in net debt by our math
The press release dropped any mention of the 2026 cash-flow breakeven goal. Reaching breakeven for the full year now requires generating $3.2 million of operating cash in the fourth quarter by our math, leaving almost no liquidity cushion if holiday collections lag.
What to watch: full-year operating cash flow and year-end cash in the annual report. Falling short of the $3.2 million fourth-quarter cash requirement would likely force another capital raise before the convertible notes mature in November 2027.
Preferred Conversions Swell the Share Count
Biofrontera funded its past losses and the October 2025 asset purchase by issuing convertible preferred stock and convertible notes. Those securities allow holders to convert their stakes into common shares at fixed prices between $0.62 and $0.78 per share.
Holders converted another large block during the third quarter, lifting common shares issued and outstanding to 17.95 million at September 30 from 14.21 million at June 30 — a 26.3% jump in three months and a 54.1% increase since December 2025 by our math. Weighted-average shares rose 41.8% from a year ago to 15.28 million, which shrank the per-share loss from $0.62 to $0.42 even though net loss barely moved.
Even after 5.69 million common shares were created from preferred stock during the first nine months, remaining Series B-2, B-3, C and D preferred shares still convert into 28.51 million common shares by our math, plus about 5.1 million shares from the convertible notes. That remaining overhang is nearly double the current share count, diluting common stockholders' claim on future skin-cancer profits.
What to watch: the preferred stock table and subsequent-event conversions in the third-quarter 10-Q filing. Continued rapid conversions would expand the common share count toward 46 million before the skin cancer launch reaches scale.
Risks this quarter didn't answer
Three standing operational and legal risks received no numeric update in the third-quarter earnings release.
- Serviceable lamp base and XL-C swaps: the release gave no updated total lamp count (801 in Q2) or how many of the ~243 banned XL lamps were replaced after the September 14 ruling; the call transcript will test this.
- Sun Pharma litigation: the release noted $0.9 million in higher ITC legal fees but gave no status on the vacated patent-review decision or the federal unfair-competition and patent lawsuits; the 10-Q legal footnote will carry the update.
- Minimum tube purchase commitment: no figure on nine-month Ameluz tube purchases against the 80,000-tube annual minimum required to prevent US product rights from reverting to Biofrontera AG; the 10-Q related-party footnote will show progress.
💲 Other KPIs
Research and development spending fell by nearly half from $0.85 million a year ago and sits at 5.0% of revenue, down 7.3 percentage points by our math. The drop follows the completion of Phase 3 actinic keratosis trials and a pause on Phase 3 acne studies until more cash is available.
Combined trade and related-party payables — bills owed to suppliers and to Biofrontera AG — rose to $7.63 million from $5.36 million in June and $6.67 million at year-end by our math. Trade payables climbed from $1.86 million at year-end to $6.90 million as the biopharmaceutical company took direct control of manufacturing and stretched supplier payments to preserve cash.
🔮 Guidance
Unchanged. Following the September 9 FDA approval, the dermatology group still plans to begin commercializing Ameluz for superficial basal cell carcinoma later in the fourth quarter and into the first quarter of 2027. Meaningful revenue from the new skin cancer indication therefore starts in 2027 rather than during the fourth-quarter seasonal peak.
❓ Key Questions
Did Biofrontera drop its 2026 cash-flow breakeven target?
Nine-month operating cash burn reached $3.2 million after a $1.5 million outflow in the third quarter, and the release omitted the prior full-year breakeven pledge. Investors need to know if management still expects at least $3.2 million of fourth-quarter operating cash flow.
How many banned XL lamps have been swapped for XL-C?
Roughly 243 RhodoLED XL lamps — 30% of the installed base — were barred from receiving new Ameluz starting July 6 until Customs cleared the redesigned XL-C on September 14. The pace of physical swaps determines how much fourth-quarter peak demand returns.
How much of July's order pull-forward came out of Q4?
Customers accelerated orders into both the second quarter and early July ahead of the July 6 import ban. Management said this shifted order timing rather than total demand, so investors need to know how much clinic inventory remains to be worked down in Q4.
Will the $1 million Xepi milestone arrive in December?
With cash down to $3.2 million and trade payables up to $6.9 million, non-dilutive cash inflows matter. Previous filings pointed to a $1.0 million payment from Pelthos Pharmaceuticals in December 2026 upon commercial availability of the divested Xepi cream.